Drugs / QazCovid-in®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04530357 | Sep → Nov 2020 | COVID-19, vaccinia | Research Institute for Biological Safety Problems | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04691908 Comparator | Dec 2020 → Apr 2021 | COVID-19 | Research Institute for Biological Safety Problems | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QAZCOVID-IN | “Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-IN®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18...” NCT04530357 ↗ |
| Modality | Vaccine | “A new inactivated whole-virion QazCovid-in® vaccine against COVID-19” PMID 34414368 ↗ Aug 2021 |
| Route | Intramuscular | “intramuscularly, at a dose of 0.5 ml” NCT04530357 ↗ |